GoodRx Launches Novo Nordisk's Wegovy HD at $399 per Month
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy GDRX?
GoodRx announced that the new higher dose Novo Nordisk's (NVO) Wegovy HD injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GDRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GDRX
Wall Street analysts forecast GDRX stock price to rise
10 Analyst Rating
4 Buy
4 Hold
2 Sell
Hold
Current: 2.350
Low
2.60
Averages
4.46
High
7.00
Current: 2.350
Low
2.60
Averages
4.46
High
7.00
About GDRX
GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GoodRx Launches FDA-Approved Foundayo Medication for Weight Management
- Drug Launch: GoodRx collaborates with Eli Lilly to introduce the FDA-approved oral GLP-1 medication Foundayo, priced at $149 per month for eligible self-pay patients, ensuring access to this highly anticipated weight management treatment with transparent cash pricing.
- Expanded Self-Pay Pricing: In addition to Foundayo, GoodRx offers self-pay pricing for Zepbound KwikPen starting at $299 per month, available at over 70,000 pharmacies, further broadening access to GLP-1 treatment options for adults seeking obesity care.
- Innovative Access Models: GoodRx's role illustrates how innovative therapies can reach patients more effectively through direct-to-consumer models, combining transparent cash pricing with nationwide pharmacy access to facilitate easier treatment initiation and continuity of care.
- Market Impact: Since 2011, GoodRx has helped Americans save over $100 billion on medication costs, and the launch of Foundayo and Zepbound is expected to enhance the company's leadership in the prescription savings platform, promoting patient acceptance of new treatment options.
See More
GoodRx Stock Jumps 5.1% in Premarket Trading Following Announcement of Self-Pay Access to Eli Lilly's New Weight-Loss Medication
GoodRx Shares Rise: GoodRx shares increased by 5.1% in pre-market trading.
New Offering Announcement: The rise follows GoodRx's announcement that it will offer self-pay access to Eli Lilly's new weight-loss pill.
See More
GOODRX INCREASES AVAILABILITY OF ELI LILLY'S NEW ORAL GLP-1, FOUNDAYO™, AND ZEPBOUND® KWIKPEN® WITH SELF-PAY PRICING AT OVER 70,000 PHARMACIES ACROSS THE COUNTRY
GoodRx Expansion: GoodRx is expanding access to its services through partnerships with Eli Lilly and Company, introducing new products to the market.
New Offerings: The company is launching the oral GLP-1 medication, FoundayO™, and the Zepbound® KwikPen®, which will be available with self-pay pricing at over 70,000 pharmacies nationwide.
See More
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
GoodRx Partners with Eli Lilly to Lower Medication Costs
- Employer Funding Model: GoodRx Employer Direct enables self-insured employers to subsidize the $449 price of Eli Lilly's Zepbound KwikPen, significantly reducing employee out-of-pocket costs and enhancing access to obesity management medications.
- Real-Time Integration Mechanism: GoodRx integrates manufacturer discounted pricing with employer funding in real time, ensuring that employer contributions are seamlessly applied to medication costs, creating a more transparent payment pathway and enhancing employer sustainability.
- Simplified Access Process: This model does not alter employers' core health benefit structures, allowing them to flexibly control subsidy amounts while offering a direct-to-consumer telemedicine solution that simplifies the GLP-1 treatment journey.
- Market Demand Response: As demand for GLP-1 obesity treatment rises, the collaboration between GoodRx and Eli Lilly demonstrates how to meet employer needs through transparent solutions, further expanding access to obesity management medications.
See More
GoodRx Launches FDA-Approved Foundayo Medication for Weight Management
- Drug Launch: GoodRx collaborates with Eli Lilly to introduce the FDA-approved oral GLP-1 medication Foundayo, priced at $149 per month for eligible self-pay patients, ensuring access to this highly anticipated weight management treatment with transparent cash pricing.
- Expanded Self-Pay Pricing: In addition to Foundayo, GoodRx offers self-pay pricing for Zepbound KwikPen starting at $299 per month, available at over 70,000 pharmacies, further broadening access to GLP-1 treatment options for adults seeking obesity care.
- Innovative Access Models: GoodRx's role illustrates how innovative therapies can reach patients more effectively through direct-to-consumer models, combining transparent cash pricing with nationwide pharmacy access to facilitate easier treatment initiation and continuity of care.
- Market Impact: Since 2011, GoodRx has helped Americans save over $100 billion on medication costs, and the launch of Foundayo and Zepbound is expected to enhance the company's leadership in the prescription savings platform, promoting patient acceptance of new treatment options.
See More
GoodRx Stock Jumps 5.1% in Premarket Trading Following Announcement of Self-Pay Access to Eli Lilly's New Weight-Loss Medication
GoodRx Shares Rise: GoodRx shares increased by 5.1% in pre-market trading.
New Offering Announcement: The rise follows GoodRx's announcement that it will offer self-pay access to Eli Lilly's new weight-loss pill.
See More
GOODRX INCREASES AVAILABILITY OF ELI LILLY'S NEW ORAL GLP-1, FOUNDAYO™, AND ZEPBOUND® KWIKPEN® WITH SELF-PAY PRICING AT OVER 70,000 PHARMACIES ACROSS THE COUNTRY
GoodRx Expansion: GoodRx is expanding access to its services through partnerships with Eli Lilly and Company, introducing new products to the market.
New Offerings: The company is launching the oral GLP-1 medication, FoundayO™, and the Zepbound® KwikPen®, which will be available with self-pay pricing at over 70,000 pharmacies nationwide.
See More
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
GoodRx Partners with Eli Lilly to Lower Medication Costs
- Employer Funding Model: GoodRx Employer Direct enables self-insured employers to subsidize the $449 price of Eli Lilly's Zepbound KwikPen, significantly reducing employee out-of-pocket costs and enhancing access to obesity management medications.
- Real-Time Integration Mechanism: GoodRx integrates manufacturer discounted pricing with employer funding in real time, ensuring that employer contributions are seamlessly applied to medication costs, creating a more transparent payment pathway and enhancing employer sustainability.
- Simplified Access Process: This model does not alter employers' core health benefit structures, allowing them to flexibly control subsidy amounts while offering a direct-to-consumer telemedicine solution that simplifies the GLP-1 treatment journey.
- Market Demand Response: As demand for GLP-1 obesity treatment rises, the collaboration between GoodRx and Eli Lilly demonstrates how to meet employer needs through transparent solutions, further expanding access to obesity management medications.
See More
